bluebird bio (BLUE) Projected to Post Quarterly Earnings on Wednesday

bluebird bio (NASDAQ:BLUE) is projected to post its Q1 2025 quarterly earnings results on Wednesday, May 7th. Analysts expect the company to announce earnings of ($2.42) per share and revenue of $39.03 million for the quarter.

bluebird bio Trading Down 1.7 %

Shares of BLUE opened at $4.12 on Wednesday. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $40.33 million, a PE ratio of -0.11 and a beta of 0.41. The stock’s fifty day simple moving average is $4.23 and its 200-day simple moving average is $6.82. bluebird bio has a 12-month low of $3.56 and a 12-month high of $28.60.

Analyst Ratings Changes

A number of equities research analysts recently commented on BLUE shares. StockNews.com initiated coverage on shares of bluebird bio in a report on Tuesday. They set a “sell” rating on the stock. Barclays dropped their price objective on bluebird bio from $40.00 to $8.00 and set an “overweight” rating on the stock in a research note on Monday, March 31st. JPMorgan Chase & Co. upgraded shares of bluebird bio from an “underweight” rating to a “neutral” rating in a research note on Monday, February 24th. Baird R W downgraded shares of bluebird bio from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 21st. Finally, Wells Fargo & Company dropped their price objective on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating for the company in a report on Monday, February 24th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, bluebird bio currently has a consensus rating of “Hold” and a consensus target price of $44.60.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.